The treatment window ChondroFiller is built for

ChondroFiller® — marketed in UK clinical settings as Liquid Cartilage™ — occupies a specific and well-defined place on the knee cartilage disease ladder. Its target is the focal, isolated articular cartilage defect: a discrete area of ICRS Grade III or IV damage sitting within a knee that still has viable, intact cartilage at the surrounding borders. Placed under ultrasound guidance as an outpatient procedure, the injectable collagen scaffold self-gels in situ and works through acellular matrix-induced chondrogenesis — drawing the patient's own progenitor cells into the matrix, where they can mature and lay down cartilage-like tissue.

That mechanism depends on two things being true simultaneously: the defect must be contained enough to hold the scaffold, and the surrounding tissue must be biologically active enough to supply the cells that populate it. ChondroFiller is not a coating for a worn-out compartment, and it cannot compensate for cartilage that is absent throughout a joint surface.

Understanding this treatment window makes the rest of this article straightforward to read. Each subsequent section describes a clinical situation that sits outside it — whether because the disease is too advanced, the joint mechanics are compromised, a biological factor is incompatible, or access is limited. These are boundaries of the indication, not shortcomings of the device.

End-stage arthritis and the case for knee replacement

'I've been told I need a knee replacement — could ChondroFiller work instead?' It is one of the most common questions at a cartilage consultation, and it deserves a straight answer: where bone-on-bone contact is established across a knee compartment, ChondroFiller is not an alternative to replacement.

The reason is mechanistic, not arbitrary. The scaffold's entire repair process depends on viable progenitor cells migrating in from the defect margins. In Kellgren-Lawrence Grade IV arthritis — where cartilage has been lost across a compartment and the articulating surfaces are in direct bony contact — that viable surrounding tissue is absent. There is no biological substrate for the scaffold to anchor to or recruit from. Placing a collagen matrix into a compartment stripped of healthy cartilage borders does not meet the conditions the treatment requires, and the clinical literature does not support ChondroFiller as a surgical implant for diffuse end-stage joint disease.

One nuance is worth clarifying. The injectable form of ChondroFiller can be used in KL Grade III–IV osteoarthritis, but with a different mechanistic goal: acting as an additive viscoelastic cushion over worn surfaces to modify the joint environment and support symptom control. That is not the same as focal cartilage regeneration, and the two applications should not be conflated. One repairs a discrete defect; the other supports a failing compartment.

For patients at the replacement threshold, the appropriate next step is a frank conversation with their surgeon about timing and implant choice. ChondroFiller occupies an earlier point on the disease ladder, and candidacy for either pathway is confirmed through imaging and clinical assessment — not by choosing between them speculatively.

Defect size, depth, and the quality of surrounding cartilage

Three structural factors determine whether a defect is suitable for ChondroFiller at the tissue level: how large the lesion is, how deep it extends, and whether the cartilage surrounding it is intact.

Defect area

The surgical implantation pathway is validated for focal defects up to 6 cm². Beyond this ceiling, the clinical evidence base does not extend, and diffuse or whole-compartment cartilage loss falls outside the surgical indication entirely. The injectable pathway carries no stated upper size limit — it can coat a broader articular surface — but area alone does not determine suitability. For focal defects of 3 cm² or more, MACI (matrix-induced autologous chondrocyte implantation) has randomised controlled trial evidence through the SUMMIT trial, with demonstrated improvements in KOOS pain and function scores at two and five years versus microfracture. That evidence sits in the background of any shared decision-making for larger focal defects — not as a reason to discount ChondroFiller, but as an honest part of the comparison.

Defect depth

ICRS Grade 4 lesions penetrate through the subchondral bone plate, changing the clinical problem from cartilage repair to osteochondral reconstruction. ChondroFiller addresses the cartilage layer; it does not rebuild underlying bone. Where significant bone loss underlies the defect, an osteochondral allograft or combined technique is the more appropriate pathway.

Border quality

Healthy surrounding cartilage is a prerequisite, not a preference. The scaffold gels in situ against the margins of the defect: without structurally intact borders to contain it, mechanical retention is not achievable. This principle applies equally to the injectable form. Where the cartilage surrounding a lesion is entirely degenerate, the conditions for both scaffold retention and progenitor-cell migration into the matrix are absent, regardless of defect size.

Alignment faults, instability, and meniscal loss

Biomechanical problems represent a different category of exclusion from the structural defect limits described above — conditional rather than absolute, and often addressable through staged care.

Varus and valgus malalignment

When the mechanical axis of the leg is malaligned — either bowing inward (varus) or outward (valgus) — load is concentrated on one side of the knee throughout every step. Placing a collagen scaffold into the affected compartment without correcting this fault means the repair site bears disproportionate stress from the moment of weight-bearing. Scaffold integration depends on a protected mechanical environment; uncorrected malalignment reliably undermines it. A high tibial osteotomy (HTO) for varus deformity, or a distal femoral osteotomy (DFO) for valgus, is a prerequisite in these cases — not an optional adjunct.

Ligament instability

The knee's ligaments protect healing tissue by governing joint kinematics and limiting abnormal translation. Where significant instability is present — whether anterior cruciate, posterior cruciate, or combined — the joint cannot provide that protection during the repair phase. Ligament reconstruction should precede or accompany cartilage treatment; proceeding without it risks early scaffold failure.

Meniscal deficit

A meniscal deficit that is actively driving cartilage loss creates an adverse load-distribution environment. The meniscus transmits roughly 50–70% of the compressive force across the joint; repairing cartilage without restoring that distribution is unlikely to produce durable results. Meniscal pathology driving the wear must therefore be addressed alongside or before scaffold placement.

Sequencing, not permanent exclusion

For patients in any of these categories, the clinical question is not whether ChondroFiller is ever suitable — it is whether corrective treatment of the mechanical fault comes first. Biomechanical assessment, including gait analysis and MRI review, can clarify which faults are present and guide the sequence of care.

Biological contraindications: collagen allergy and active inflammation

Two biological factors can make ChondroFiller unsuitable regardless of defect size or joint mechanics — one is an absolute contraindication, the other a clinical inference grounded in how the scaffold works.

Murine collagen allergy

ChondroFiller is made from murine-derived Type I collagen — that is, collagen sourced from rodent tissue. Patients with a known allergy or hypersensitivity to mouse- or rodent-derived proteins cannot receive this treatment. This is a straightforward product-composition issue: the biological material that forms the scaffold is the allergen. Anyone with a history of reactions to animal-derived collagen products should flag this before assessment, as it closes off ChondroFiller specifically while leaving other injectable pathways open.

Inflammatory arthritis and the repair environment

Active inflammatory joint disease — rheumatoid arthritis, psoriatic arthritis, and similar conditions — creates a joint environment that may work against scaffold colonisation. The mechanism is relevant here: ChondroFiller recruits progenitor cells from the margins of a defect, which then mature within the collagen matrix. Persistent synovitis produces an inflammatory milieu that degrades this biological substrate, potentially preventing the cellular activity the scaffold depends on.

This is not a formally published contraindication in the same way that collagen allergy is. It is a clinical position derived from what the scaffold requires to work — and clinically, active inflammatory disease that is not under rheumatological control is a reason to pause any cartilage repair, ChondroFiller included. Patients with well-managed inflammatory arthritis are a different matter; the concern is specifically uncontrolled synovitis and ongoing joint inflammation.

For those patients, bringing the inflammatory condition under rheumatological control is the necessary first step before any cartilage repair pathway is meaningfully evaluated.

Cost, access, and what to do if ChondroFiller is not the right fit

Funding is a practical filter that sits alongside the clinical ones, and it is worth stating plainly. ChondroFiller / Liquid Cartilage is self-funded private treatment in the UK — it is not commissioned by the NHS and is typically not covered by private medical insurance. Guide costs start from approximately £3,000, confirmed by the treating clinic at assessment. For many patients, this is the first question; having the answer early helps with realistic planning.

Where clinical candidacy is the barrier, the appropriate alternative depends on the reason:

• End-stage disease: where cartilage is no longer salvageable, knee replacement is the established answer — and the right one.
• Mechanical faults present: osteotomy, ligament reconstruction, or meniscal treatment addressed first may subsequently make cartilage repair viable.
• Large focal defects: for defects of 3 cm² or more, MACI has RCT-level evidence from the SUMMIT trial and may represent a more established surgical route.
• Symptomatic management: hyaluronic acid or PRP injections can reduce pain and support joint function where structural repair is not indicated.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. A clinical assessment — including MRI review — will clarify which pathway is appropriate and whether any conditional exclusion can be resolved. Book at lincolnshireknee.co.uk.